Annual Report 2011 of Beximco Pharmaceuticals Limited

It is a broadly described annual report of Beximco Pharmaceuticals Limited in the year of 2011. During the year BPL achieving a 21.6% increase in sales to Taka. 7,890.24 million (2010: Tk. 6,490.85 million). Sales of the company’s Active Pharmaceutical Ingredients (APIs) also recorded a significant 37.1% growth to reach Taka. 486.91 million (2010: Tk. 355.24 million). In 2011 export sales grew by 18.1% to Taka. 390.32 million (2010: Tk. 330.54 million). Along with sales growth, Beximco Pharma also achieved a marked growth in profit in 2011. The Company’s pre-tax profit increased 23.2% to Taka. 1,677.85 million (2010: Tk. 1,361.53 million).

The Board of Directors has recommended 21% stock dividend for approval of the shareholders for the year ended 31st December 2011. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Beximco Pharmaceuticals Limited :

  1. Annual Report 2001 of Beximco Pharmaceuticals Limited
  2. Annual Report 2002 of Beximco Pharmaceuticals Limited
  3. Annual Report 2003 of Beximco Pharmaceuticals Limited
  4. Annual Report 2004 of Beximco Pharmaceuticals Limited
  5. Annual Report 2005 of Beximco Pharmaceuticals Limited
  6. Annual Report 2006 of Beximco Pharmaceuticals Limited
  7. Annual Report 2007 of Beximco Pharmaceuticals Limited
  8. Annual Report 2008 of Beximco Pharmaceuticals Limited
  9. Annual Report 2009 of Beximco Pharmaceuticals Limited
  10. Annual Report 2010 of Beximco Pharmaceuticals Limited
  11. Annual Report 2011 of Beximco Pharmaceuticals Limited
  12. Annual Report 2012 of Beximco Pharmaceuticals Limited
  13. Annual Report 2013 of Beximco Pharmaceuticals Limited
  14. Annual Report 2014 of Beximco Pharmaceuticals Limited
  15. Auditors’ Report 2015 of Beximco Pharmaceuticals Limited
  16. Annual Report 2016 of Beximco Pharmaceuticals Limited
  17. Auditors’ Report 2017 of Beximco Pharmaceuticals Limited